NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).

被引：43
|
作者：
Slamon, Dennis J.
Fasching, Peter A.
Patel, Ravindranath
Verma, Sunil
Hurvitz, Sara A.
Chia, Stephen K. L.
Crown, John
Martin, Miguel
Barrios, Carlos H.
Spera, Gonzalo
Lopez, Celine
Hor, Ines
Pelov, Diana
Hughes, Gareth
Nawinne, Moditha
Hortobagyi, Gabriel N.
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Hosp Erlangen, Erlangen, Germany
[3] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[5] BC Canc Agcy, Vancouver, BC, Canada
[6] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[8] Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil
[9] Translat Res Oncol, Montevideo, Uruguay
[10] Translat Res Oncol TRIO, Paris, France
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharma AG, Basil, Switzerland
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS597
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Overcoming resistance to endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: A meta-analysis of randomized clinical trials
    Zhu, W.
    Xu, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S74 - S74
  • [42] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Gelmon, Karen A.
    Cristofanilli, Massimo
    Rugo, Hope S.
    DeMichele, Angela M.
    Joy, Anil A.
    Castrellon, Aurelio
    Sleckman, Bethany
    Mori, Ave
    Theall, Kathy Puyana
    Lu, Dongrui R.
    Huang, Xin
    Bananis, Eustratios
    Finn, Richard S.
    Slamon, Dennis J.
    BREAST JOURNAL, 2020, 26 (03): : 368 - 375
  • [43] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen
    Fasching, Peter A.
    De Laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Val
    Esteva, Francisco J.
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    De la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Karen Rodriguez
    Miller, Michelle
    Taran, Tetiana
    Jerusalem, Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2465 - +
  • [45] Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials
    Goetz, Matthew P.
    Okera, Meena
    Wildiers, Hans
    Campone, Mario
    Grischke, Eva-Maria
    Manso, Luis
    Andre, Valerie Anne Marie
    Chong, Amy Lee
    San Antonio, Belen
    Toi, Masakazu
    Sledge, George W., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [46] HORMONE RECEPTOR-POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER (ABC): TESTING PATTERNS, PRESCRIBING BEHAVIOR, AND TREATMENT OPTION PERCEPTIONS AMONG US ONCOLOGISTS
    Miller, T.
    Savill, K.
    Jeune-Smith, Y.
    Leon, B.
    Brown, M.
    Klink, A.
    Feinberg, B.
    VALUE IN HEALTH, 2022, 25 (12) : S277 - S277
  • [47] Ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
    DeLaurentiis, Michelino
    Neven, Patrick
    Jerusalem, Guy Heinrich Maria
    Bachelot, Thomas Denis
    Jacot, William
    Dent, Susan Faye
    Colleoni, Marco
    Prat, Aleix
    Martin, Miguel
    Ring, Alistair E.
    Cottu, Paul H.
    Lu, Janice M.
    Azim, Hamdy A.
    Zhou, Katie
    Wu, Jiwen
    Zarate, Juan Pablo
    Zamagni, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Mistry, R.
    Suri, G.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A422 - A423
  • [49] Working tables on Hormone Receptor positive (HR plus ), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence
    Zambelli, A.
    Gallerani, E.
    Garrone, O.
    Pedersini, R.
    Caremoli, E. Rota
    Sagrada, P.
    Sala, E.
    Cazzaniga, M. E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 191
  • [50] A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
    Llombart, Antonio
    Toi, Masakazu
    Klise, Suzanne R.
    Frenzel, Martin
    Chan, Edward M.
    Sledge, George W.
    CANCER RESEARCH, 2015, 75
12345